Soligenix, INC.: directors' dealings · United States · SEC (Form 4)

About Soligenix, INC.

Soligenix, Inc. is a specialty biopharmaceutical company listed on the Nasdaq Capital Market under the ticker SNGX in the United States. For French-speaking investors, it fits the profile of a development-stage biotech: valuation is primarily driven by clinical milestones, regulatory progress, and financing capacity rather than recurring product revenue. The company has operated under several legacy names before adopting Soligenix, Inc. in 2009, reflecting a long corporate history in life sciences. Its principal executive office is in Princeton, New Jersey, United States. Soligenix describes itself as a late-stage biopharmaceutical company focused on rare diseases and other areas of unmet medical need. The business is organized into two segments. Specialized BioTherapeutics is the core value-creation engine and houses the company’s lead therapeutic programs. Its flagship asset is HyBryte™, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma (CTCL), a rare form of skin lymphoma. The company is also developing SGX302 for psoriasis, alongside its Innate Defense Regulator platform, including SGX942 for oral mucositis in head and neck cancer and SGX945 for aphthous ulcers associated with Behçet’s disease. The second segment, Public Health Solutions, includes biodefense and public-health programs such as RiVax®, a ricin toxin vaccine candidate, as well as work targeting viral threats including Ebola, Marburg, and certain coronavirus programs. From a competitive standpoint, Soligenix occupies a highly specialized niche where differentiation depends on science, intellectual property, and clinical validation. Its investment case is built around orphan and underserved indications, where market size may be limited but pricing power and regulatory incentives can be attractive if clinical proof is achieved. HyBryte™ is the main program to watch. The company has advanced the asset through phase 3 development, and its recent disclosures indicate a confirmatory Phase 3 FLASH2 study is underway. That makes the name particularly sensitive to trial design, enrollment pace, interim readouts, and the ability to convert clinical progress into a viable regulatory path. Recent events reinforce the company’s development-stage profile. Soligenix began patient enrollment in FLASH2 in December 2024, and SEC filings indicate an interim analysis is expected in the second quarter of 2026, with top-line results anticipated in the second half of 2026. The company also completed financing transactions in 2025, underscoring that access to capital remains central to execution. For investors following U.S.-listed biotech names on the Nasdaq, Soligenix is best viewed as a clinical catalyst story with multiple pipeline shots on goal, but with meaningful dilution and execution risk until a clear regulatory and commercial path is established.